Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viyash ScientificNSE:VIYASH -4.00%69 EV-to-EBITDA is 19.69 as of Aug. 17, 2026, which is 9% below its 10-year median of 21.58. GuruFocus rates NSE:VIYASH with a GF Score™ of 69/100 and a GF Value™ of ₹173.06 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 734 Drug Manufacturers companies, Viyash Scientific ranks worse than 66.49% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Viyash Scientific's enterprise value is ₹116,414 Mil.
Viyash Scientific's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹5,913 Mil. Therefore, Viyash Scientific's EV-to-EBITDA for today is 19.69.
The historical rank and industry rank for Viyash Scientific's EV-to-EBITDA or its related term are showing as below:
NSE:VIYASH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -79.65 Med: 21.58 Max: 71.48
Current: 19.69
During the past 13 years, the highest EV-to-EBITDA of Viyash Scientific was 71.48. The lowest was -79.65. And the median was 21.58.
NSE:VIYASH's EV-to-EBITDA is ranked worse than 66.49% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.325
vs NSE:VIYASH: 19.69
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Viyash Scientific's PE Ratio (TTM) for today is calculated as:
Viyash Scientific's share price for today is ₹255.65.
Viyash Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Viyash Scientific's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Viyash Scientific's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viyash Scientific EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viyash Scientific's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viyash Scientific's EV-to-EBITDA falls into.
Viyash Scientific's current Enterprise Value is ₹116,414 Mil.
Viyash Scientific's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,913 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viyash Scientific (NSE:VIYASH) has a EV-to-EBITDA of 19.69 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Viyash Scientific. This is near median its historical median of 21.58. According to the industry distribution chart, Viyash Scientific ranks #488 out of 734 companies in the Drug Manufacturers industry, placing it in the top 66.5%.
Is Viyash Scientific's EV-to-EBITDA too high?
Viyash Scientific's current EV-to-EBITDA of 19.69 is near median its 10-year median of 21.58. The Drug Manufacturers industry median EV-to-EBITDA is 13.33. Viyash Scientific's value of 19.69 is 47.8% above this industry median. Based on the distribution chart, Viyash Scientific ranks #488 out of 734 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Viyash Scientific has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viyash Scientific's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Viyash Scientific ranks #488 out of 734 companies for EV-to-EBITDA. This places Viyash Scientific in the lower half of its industry. The industry median EV-to-EBITDA is 13.33. Viyash Scientific's value of 19.69 is 47.8% above this benchmark. While the company's 10-year median is 21.58 vs. the industry median of 13.33, Viyash Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viyash Scientific's current EV-to-EBITDA of 19.69 is 47.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Viyash Scientific. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viyash Scientific's current EV-to-EBITDA is 19.69, which is near median its own 10-year median of 21.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viyash Scientific stock overvalued right now?
Based on GuruFocus' analysis, Viyash Scientific (NSE:VIYASH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹173.06, compared to a current price of ₹255.65 — trading 47.7% above its estimated fair value. The current EV-to-EBITDA is 19.69, which is near median its 10-year median of 21.58 and 47.8% above the Drug Manufacturers industry median of 13.33. Viyash Scientific's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Viyash Scientific (NSE:VIYASH), the current EV-to-EBITDA is 19.69 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viyash Scientific (NSE:VIYASH) Overvalued in 2026?
Based on GuruFocus' analysis, Viyash Scientific stock appears to be overvalued.
The current stock price of ₹255.65 is trading 47.7% above its estimated GF Value™ of ₹173.06.
GuruFocus considers Viyash Scientific to be Significantly Overvalued.
Key valuation signals for NSE:VIYASH:
EV-to-EBITDA: 19.69 (near median its 10-year median of 21.58)
GF Value™: ₹173.06 vs. price of ₹255.65 (47.7% above fair value)
Industry Position: 47.8% above the Drug Manufacturers median (#488 of 734)
No single metric tells the full story. See the NSE:VIYASH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viyash Scientific Ltd is a pharmaceutical company with activities spanning formulations, active pharmaceutical ingredients (APIs), and intermediates. It is focused on research and development infrastructure for APIs and formulations. Its product portfolio spans several therapeutic areas, including ARV, cardiovascular, central nervous system, analgesics, antibiotics, antihistamines, diabetes, gastrointestinal, anticoagulants, and oncology.
69GF Score
Get the complete analysis for NSE:VIYASH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VIYASH has been successfully added to your 
